Global Cervical Cancer Diagnostics and Therapeutic Market - Segmented by diagnostic test, method, end user, therapy and geography (2014-2020)

Mar 08, 2016, 18:32 ET from Reportlinker

NEW YORK, March 8, 2016 /PRNewswire/ -- The global cervical cancer market was valued at USD 2,140 million in 2015 and is expected to grow at a CAGR of 2-5% during 2015 to 2020.

Cervical cancer is generally characterized by the abnormal growth of cancerous cells in the tissues of the cervix, and it may manifest itself as a squamous-cell carcinoma or adenocarcinoma. According to the World Health Organization (WHO), cervical cancer accounts for the deaths of more than 270,000 women annually, primarily in the developing countries. With the increasing use of cervical cancer diagnostic tests such as pap smear tests, HPV testing and colposcopy for early detection, the market is highly competitive, with high growth rate.

The advent of technologically advanced computer-guided screening tests for cervical cancer, in order to reduce the rate of false-negative results, and improved accuracy are expected to contribute to the growth of the cervical cancer diagnostic tests market during the forecast period, from 2014 to 2020.

The global cervical cancer diagnostic and therapeutic market is segmented on the basis of:

Diagnostics test
Pap smear test
HPV testing
Cervical cancer biopsy
Molecular method
Cytopathological method
Physical method
Independent physicians
Radiation therapy
Geographical Region
North America
Rest of the world
North Americas is expected to account for almost 49% of the total market share by 2020.

Some of the key players of cervical cancer diagnostics and therapeutics market are Abbott diagnostics, Becton Deckinson and company, Roche, Siemens Healthcare, Autogenomics, Biolight meditech, Cooper surgical, cancer genetics, EDP Biotech, Companion DX, Genomic tree, Metabiomics, Exact sciences etc.


Rising prevalence of cervical cancer
Favourable government initiatives
Funding to increase disease awareness
Increase of pipeline cervical cancer screening tests
Aging population
Increasing consumer awareness


Cost of screening test
Availability of HPV vaccines
Uncertain reimbursement rates
Changes in regulatory guidelines
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker